|
所在平台: Udemy |
课程主页: https://www.udemy.com/course/advances-in-lung-cancer-treatment-an-organized-review-cme/
课程评论：没有评论
**课程总结：肺癌治疗新进展——组织化回顾 (CME/CNE 认证，3小时)** 本课程由 Tyler Greenfiled 博士主讲，旨在为学员提供肺癌治疗领域的最新见解，特别是针对复发预防和延长无病生存期的围手术期（术前和术后）优化治疗策略。 **课程亮点：** * **全面理解最新疗法：** 深入探讨最新的术前和术后治疗方法，以预防肺癌复发并延长无病生存期。 * **免疫疗法与靶向疗法：** 详细介绍免疫疗法和靶向疗法在肺癌治疗中的作用。 * **最新研究与进展：** 剖析最新的研究成果和疗法进展，及其对患者护理的影响。 * **治疗回顾与展望：** 简要回顾过往的治疗类型，并详细阐述个体化分子靶点治疗及其可用药物。 * **免疫系统与癌症治疗：** 深入探讨免疫系统与癌细胞的相互作用，以及用于改变这些相互作用的药物。 * **生物标志物检测的重要性：** 强调生物标志物检测以及进一步临床研究的意义。 * **未来研究方向：** 展望肺癌治疗领域的未来研究方向。 **学习目标：** 完成本课程后，学员将对预防肺癌复发和延长无病生存期的最先进的围手术期治疗有深刻的理解。同时，将能够扎实掌握肺癌治疗的最新研究和进展，并将其应用于优化患者的治疗效果。
NOW CME & CNE Accredited - 3 Hours Optimizing Lung Cancer Surgery Outcomes: An organized review of Advanced Pre and Post-Operative Treatment for Recurrence Prevention and Extending Disease-Free Survival Here's what you can expect to learn from this course:A comprehensive understanding of the latest pre and post-operative treatments for lung cancer recurrence prevention and disease-free survival extension.An in-depth discussion of the role of immunotherapy and targeted therapy in the context of lung cancer treatment.The latest research and advancements in lung cancer treatment, and how they impact patient care.Brief review of previous types of treatmentsDetailed discussion of individual molecular targets for treatment and the different drugs available to treat each of these targetsDetailed discussion of the interaction of the immune system with cancer cells and drugs used to alter these interactions for the treatment of lung cancerImportance of Biomarker Testing and Further Clinical InvestigationsFuture directions for researchBy the end of this course, you'll have gained valuable insights into the most advanced pre and post-operative treatments for lung cancer recurrence prevention and disease-free survival extension. You'll also have a solid understanding of the latest research and advancements in lung cancer treatment, and how to apply them to optimize patient outcomes.Dr. Tyler Greenfiled
